[Source: Medical News Today] – InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced that it has developed IXS312(VEGF), an antibody fragment with activity against the growth factor VEGF for planned use in ocular treatments.
For more information: InNexus Announces Discovery Of Novel Protein For AMD Eye Disorder – Will Bypass Needles With Topical Application